ArticleSeizure2025
Elevated neuroinflammation and region-specific clinical correlates in drug-resistant focal epilepsy.
Article in Seizure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Changing Paradigm of Neuroinflammation in Epilepsy: A Bibliometric Analysis from Microglial Activation to Gut-Brain Axis.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeApproximately one-third of patients with epilepsy become refractory to traditional anti-seizure medications. Evidence from animals and in humans suggests a bidirectional relationship between epilepsy and neuroinflammation, offering potential as a novel therapeutic pathway. This study investigates region-specific relationships between neuroinflammation and medication-refractory focal epilepsy using [
methodsPatients aged 18-55 years and age-matched typical control participants were recruited for this cross-sectional study from the from the UW Health Epilepsy Monitoring Unit or the Dane County, Wisconsin area. Patients demonstrated no gross abnormalities on MRI other than hippocampal sclerosis and patients received a diagnosis of focal epilepsy. Clinical variables were obtained from chart review, interviews, and a patient seizure log. Imaging data were acquired on a GE Signa 3T PET/MR system, processed using PETSurfer, and FEPPA binding was quantified from motion-corrected PET images using standard uptake values (SUVs).
resultsAnalysis excluded participants with low binding affinity based on TSPO genetic polymorphism (n = 2 controls) or missing imaging data (n = 4), resulting in 12 patients (age=38.3 ± 13.1 years, 4 female) and 9 typical controls (age=35.2 ± 10.2 years, 4 female). Patients with epilepsy showed widespread increases in FEPPA uptake compared to controls. Significant region-specific correlations were revealed between FEPPA uptake and seizure frequency, recency, duration, and lifetime focal-to-bilateral tonic-clonic seizures. In one patient with frontal lobe epilepsy and pre- and post-ictal scans, greater mesiotemporal uptake was observed following seizure relative the interictal period, suggestive of secondary epileptogenesis. FEPPA did not correlate with systemic inflammatory markers.
conclusionFindings detail a region-specific interplay between neuroinflammation, seizure activity, and recovery in focal epilepsy. Reductions in entorhinal cortex [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.